Celcuity upped to Buy at Wainwright, price target raised to $165 from $94 on gedatolisib potential

 

• H.C. Wainwright cites gedatolisib’s potential as a game-changing therapy for HR+/HER2- advanced breast cancer.
• Phase 3 VIKTORIA-1 met its primary endpoint, showing statistically significant progression-free survival benefit versus alpelisib in PIK3CA-mutant HR+/HER2- disease.
• Celcuity plans to submit VIKTORIA-1 gedatolisib data in a supplemental NDA to the FDA.

https://finviz.com/quote?t=CELC&p=d